Catyalyst Pharma (CPRX) Tops Q2 EPS by 2c

Catyalyst Pharma (NASDAQ: CPRX) reported Q2 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Catyalyst Pharma (CPRX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• McDonald's (MCD) PT Lowered to $320 at UBS
• CLSA Reiterates Outperform (2) Rating on CSL Ltd. (CSL:AU) (CMXHF)